The FDA has an ongoing Class II recall covering multiple compounded semaglutide multi-dose vials from a single US compounding firm, Apollo Care, initiated on 19 August 2026. The stated reason is the presence of particulate matter, identified as nylon or polyamide and silk or proteinaceous-type material. The recall spans several strengths and vial sizes, including preparations formulated with glycine.
A Class II recall means the product may cause temporary or medically reversible harm, with a remote probability of serious consequences - the middle tier, not the most severe. For an injectable, particulate matter carries risks of local reaction and, less commonly, of embolic or inflammatory events. The status is recorded as ongoing.
The wider point is about the supply route rather than this firm. Compounded semaglutide exists because demand outran licensed supply, and a compounded multi-dose vial is not the same product as a licensed pen: different formulation, different container, different quality oversight. Patients rarely volunteer where a GLP-1 preparation came from, and the vial is often the giveaway - licensed semaglutide is not supplied as a multi-dose vial with a syringe. Ask, and ask specifically, before assuming that a patient reporting problems is reacting to the drug itself.
- Ask patients on a GLP-1 receptor agonist what the product looks like - a multi-dose vial and syringe is not licensed semaglutide.
- Record the source and product name in the notes, not just the drug and dose.
- Treat local injection-site reactions in someone using a compounded preparation as a possible product problem, not only a drug effect.
- This is a US recall of a US compounding firm's product; it says nothing directly about supply elsewhere.
- Where a patient has obtained a preparation outside the regulated supply chain, the safest advice is to stop it and move to a licensed product.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free